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Epilepsies are characterized by abnormal electrophysiological activity of the brain.
Among various types of inherited epilepsies different epilepsy syndromes, among
them progressive myoclonus epilepsies with features of ataxia and neurodegeneration,
are counted. The progressive myoclonus epilepsy of type 1 (EPM1), also known as
Unverricht-Lundborg disease presents with features of cerebellar atrophy and increased
oxidative stress. It has been found that EPM1 is caused by mutations in human
cystatin B gene (human stefin B). We first describe the role of protein aggregation in
other neurodegenerative conditions. Protein aggregates appear intraneurally but are also
excreted, such as is the case with senile plaques of amyloid-β (Aβ) that accumulate in
the brain parenchyma and vessel walls. A common characteristic of such diseases is
the change of the protein conformation toward β secondary structure that accounts for
the strong tendency of such proteins to aggregate and form amyloid fibrils. Second, we
describe the patho-physiology of EPM1 and the normal and aberrant roles of stefin B
in a mouse model of the disease. Furthermore, we discuss how the increased protein
aggregation observed with some of the mutants of human stefin B may relate to the
neurodegeneration that occurs in rare EPM1 patients. Our hypothesis (Ceru et al., 2005)
states that some of the EPM1 mutants of human stefin B may undergo aggregation in
neural cells, thus gaining additional toxic function (apart from loss of normal function).
Our in vitro experiments thus far have confirmed that four mutants undergo increased
aggregation relative to the wild-type protein. It has been shown that the R68X mutant
forms amyloid-fibrils very rapidly, even at neutral pH and forms perinuclear inclusions,
whereas the G4R mutant exhibits a prolonged lag phase, during which the toxic prefibrillar
aggregates accumulate and are scattered more diffusely over the cytoplasm. Initial
experiments on the G50E and Q71P missense EPM1 mutants are described.
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INTRODUCTION
Epilepsy is a chronic neurological disorder. An epileptic seizure
is a transient phenomenon, due to excessive neuronal activity.
Classification of different epilepsies is difficult and constantly
changing but a rough classification divides them into two major
groups of syndromes. The first is a symptomatic epilepsy syn-
drome in which the epileptic seizures are the result of one or
more lesions in the brain. The second group comprises idio-
pathic epilepsy syndrome, with no underlying structural brain
lesions or other neurological signs or symptoms. This latter is
presumed to be age and genetic dependent, the genetic epilep-
sies account for only about 1% of all epilepsies but usually
present with severe symptoms and have a poor outcome. The
most commonly mutated genes in genetic epilepsies are those
coding for protein subunits of voltage-gated (e.g., sodium-gated
or calcium-gated) or ligand-gated ion channels (Meisler and
Kearney, 2005). These mutations can cause impaired excitability
of inhibitory GABAergic interneurons (Rhodes et al., 2004) or
hyper excitability of firing neurons (Escayg et al., 2000) which, in
either case, disrupts currents in the brain. During excessive acti-
vation, glutamate, an excitatory neurotransmitter, causes exces-
sive calcium release that acts on N-methyl-D-aspartate (NMDA)
receptors. These are present in large quantities in the hippocam-
pus and thus extremely vulnerable to epileptic seizures and
neurodegeneration.
However, mutations other than channel-related ones have
been linked to epilepsies. Progressive myoclonic epilepsies
(PMEs) are a group of genetic generalized epilepsies with symp-
toms such as myoclonic and tonic-clonic seizures, dementia and
progressive neurodegeneration of gray matter [for reviews see
(Shahwan et al., 2005; Ramachandran et al., 2009)]. PMEs can be
divided pathogenetically into two groups: non lysosome-related,
such as Lafora disease, and lysosome-related, such as Unverricht-
Lundborg disease progressive myoclonus epilepsy of type one
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(EPM1), the most common of all PMEs and the subject of our
research. The underlying cause of the appearance of EPM1 is a
mutant encoding a cystatin B (stefin B) gene. We later describe
the EPM1 mutants, which are aggregation prone in vitro and in
cells. The hypothesis that this would correlate with more severe
cases of EPM1 pathology awaits further confirmation with patient
samples.
Protein aggregation to amyloid fibrils is a generic property
of proteins (Dobson, 2002), as it has been shown that most
proteins, even some α-helical proteins such as myoglobin, can
form amyloid-like fibrils. The parts with α helical structure must
undergo an α to β transition and the β strands then associate
into a fibrillar structure, winding into a β-sheet as protofilaments.
Fibril formation has also been observed for proteins which are
natively unfolded (intrinsically disordered) (Uversky, 2008) or are
predominantly in the β sheet conformation; some of these fold
via an α helical intermediate. Different proteins can follow differ-
ent pathways to amyloid fibrils, depending on the structural class
(Zerovnik, 2002; Zerovnik et al., 2011).
Amyloid fibril formation is a process at the core of neu-
rodegenerative diseases, from Alzheimer’s disease (AD) and
Parkinson’s disease (PD) to various other dementias such as
Huntington’s disease (HD) and amyotrophic lateral sclerosis,
but also prion-related diseases and certain hereditary types of
epilepsy. Directly or indirectly, most neurodegenerative diseases
as a class of conformational disorders (Zerovnik, 2002; Irvine
et al., 2008) are connected to aberrant protein folding, accompa-
nied by protein aggregation. The aggregation can be caused by a
mutation (in inherited cases) or by cellular stress and diminishing
clearance systems with age (in sporadic cases).
A hallmark of neurodegeneration diseases is loss of memory
(Lesne et al., 2006), which is observed long before the major neu-
rodegenerative changes occur in the brain and is to some extent
reversible, and therefore accessible to suitable therapy. It is sup-
posed that the pathology at the cellular level is spread from neural
axon to the synapse itself and influences the processes of long term
potentiation (LTP) (Walsh et al., 2002; Cleary et al., 2005; Miller
et al., 2009). It has been shown that neurodegenerative diseases
are accompanied by increased oxidative stress and inflammation
caused by glia cells activation.
PROGRESSIVE MYOCLONUS EPILEPSY OF TYPE 1 (EPM1)
AS A NEURODEGENERATIVE DISEASE
EPM1 or Unverricht-Lundborg disease is a type of progres-
sive myoclonus epilepsy (PME), a group of etiologically and
clinically heterogeneous inherited disorders sharing a combina-
tion of myoclonus, epilepsy, and progressive neurological deteri-
oration (Berkovic et al., 1986). Symptoms range from progressive
myoclonic jerks and frequent tonic-clonic seizures, to progres-
sive decline in cognition. EPM1 occurs mainly in Baltic and
Mediterranean regions and the onset of the disorder is between
6 and 18 years of age. Initially, patients are mentally alert,
showing liability, depression and, later, a mild decline in intel-
lectual performance is observed. However, the disease can lead
to dysarthria, and ataxia in later stages (Kalviainen et al., 2008;
Genton, 2010). Pathology results in a marked loss of Purkinje
cells in the granular layer of the cerebellum (Eldridge et al.,
1983).
EPM1 is inherited in an autosomal recessive manner.
Mutations in the gene encoding cystatin B (CSTB), (we use
the alternative name: stefin B throughout), a cysteine protease
inhibitor, are responsible for the primary defect underlying EPM1
(Pennacchio et al., 1996; Lalioti et al., 1997a). The most common
change found is the dodecamer repeat expansion in the promoter
region (Lalioti et al., 1997b), which leads to reduced mRNA and
protein levels. The CSTB gene is located in chromosome 21q22.3
and altogether 10 different mutations of this gene have been
reported to underlie EPM1, as shown in Table 1 (Joensuu et al.,
2008).
Since the early symptoms can often be mistaken for more
common epilepsy types, for example, juvenile myoclonic epilepsy
(JME), it is not currently possible to diagnose EPM1 without a
genetic test (De Haan et al., 2004).
DISEASE DEVELOPMENT AND PROGRESSION
Stefin B deficient mice (knock-out – KO mice) serve as a model
for EPM1, although they lack some of the symptoms typically
observed in human patients. KO mice develop myoclonus at
1 month and ataxia at 6 months of age but no tonic-clonic
seizures. Myoclonus occurs only during sleep and no photosen-
sitivity nor spike-wave complexes in the electroencephalogram
Table 1 | Mutations in CSTB underlying Unverricht-Lundborg disease (EPM1) (Joensuu et al., 2008).
Mutation (nucleotide change) Location of mutation in gene/type Predicted consequence for the protein (amino acid change)
dodecamer repeat expansion 5’ UTR/expansion reduced CSTB expression
10G>C exon 1/missense G4R
67–1G>C intron 1/splice site delV23_K56
149G>A exon 2/missense G50E
168>A exon 2/splice site aberrant splicing?
169–2A>G intron 2/splice site aberrant splicing?
168 + 1_18del intron 2/deletion delV23_K56 p.V57EfsX28
202C>T exon 3/nonsense R68X
218_219delTC exon 3/deletion L73FSX3
212A>C exon 3/missense Q71P
Reproduced from Polajnar et al., 2012.
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(EEG) are detected (Pennacchio et al., 1998). The hippocampal
slices from KO mice are hyperexcitable and more susceptible to
kainate-induced tonic-clonic seizures (Franceschetti et al., 2007).
Moreover, mice like human patients, show a progressive decrease
in neocortex thickness and loss of inhibitory GABA interneurons
(Buzzi et al., 2012).
In a developing rat brain, stefin B protein is present in glial cells
such as differentiated oligodendrocytes and astrocytes. Stefin B
is not expressed in detectable amounts in the cerebellum, except
in Purkinje cells of developing and adult rat brain (Riccio et al.,
2005). Similarly, in human cerebellum, stefin B resides in Purkinje
and Bergmann glial fibers and in the cerebral cortical neurons
of the dentate gyrus of the hippocampus. Purkinje cells are
GABAergic inhibitory neurons located in the cerebellar cortex
and are particularly prone to damage in stefin B KO mice and
EPM1 patients (Eldridge et al., 1983; Pennacchio et al., 1998;
Franceschetti et al., 2007). Increased excitation of firing neurons
due to imbalance between firing and inhibitory neurons is one
of the main general causes predicted to underlie all epilepsies.
Furthermore, patients show cerebral atrophy and reduced levels
of the grey matter in the motor cortex and thalami. Reduced cor-
tical thickness has also been observed (Koskenkorva et al., 2009).
Interestingly, the disease has been linked to obesity (Korja et al.,
2010). Although stefin B was suggested to play a protective role
against apoptosis (Kopitar-Jerala et al., 2005; Yang et al., 2010),
it is still unclear how the reduced protein levels could lead to
myoclonus and/or the epileptic phenotype with tonic-clonic light
sensitive seizures. It was suggested that primary stefin B deficit
could trigger several secondary processes, such as overstimulation
of serotoninergic transmission (Vaarmann et al., 2006) or a defect
in dopamine transmission (Korja et al., 2007), which would in
turn cause the seizure phenotype in EPM1.
It has been reported that stefin B can be found in both the
cytosol and the nucleus (Riccio et al., 2005; Ceru et al., 2010b),
although some authors (Kaur et al., 2010; Yang et al., 2011) did
not observe nuclear staining. In a search for its nuclear func-
tion, in an astrocytoma cell line T98G stefin B was found to be
expressed in the nucleus as well as in the cytosol. Furthermore,
it was shown that stefin B interacts with cathepsin L and his-
tones in the nucleus (Ceru et al., 2010a). In synchronized T98G
cells, stefin B co-immunoprecipitated with histones H2A.Z, H2B,
and H3, predominantly in the G1 phase of the cell cycle. Stefin
B-deficient mouse embryonic fibroblasts entered S phase earlier
than wild type mouse embryonic fibroblasts. Increased expres-
sion of stefin B in the nucleus delayed cell cycle progression, which
was associated with the inhibition of cathepsin L in the nucleus,
as judged from the decreased cleavage of the CUX1 transcription
factor. It was also shown that cells isolated from stefin B deficient
animals were more sensitive to staurosporin induced apoptosis
than control cells from the wild type animals (Kopitar-Jerala et al.,
2005). Whether nuclear or cytosolic functions of stefin B are asso-
ciated with increased sensitivity to apoptosis in stefin B deficient
cells is not yet clear (Abramov and Duchen, 2005).
In most cases the EPM1 mutants lead to lower expression of
stefin B mRNA and protein, whose primary function is inhibi-
tion of the cysteine proteases. Loss of function symptoms are
observed that are relatively well recapitulated in stefin B KOmice.
(Kaur et al., 2010) have shown an increase in cathepsin B and D
activities in the brain of stefin B KO mice, previously shown to
play a role in apoptosis. Moreover, overexpression of cystatin C
in these mice reduces the activity of the cathepsins to normal
levels and reduces the clinical symptoms and neuropathologies
observed in the stefin B KO mice, including motor coordination
disorder, cerebellar atrophy, neuronal loss in the cerebellum and
cerebral cortex, and gliosis. This partially explains the patholo-
gies appearing in the KO mice. However, double KO mice of
cathepsin B and stefin B still present with some residual apop-
tosis (Houseweart et al., 2003) in accordance with some loss of
function other than protease inhibition.
It is therefore important to clarify the protein’s alternative
function(s), such as in the multiprotein complex important in
the regulation of the cytoskeleton (Di Giaimo et al., 2002) and
protection of neurons against oxidative stress (Lehtinen et al.,
2009). Chaperone-like functions (Skerget et al., 2010; Taler-Vercic
and Zerovnik, 2010) have also been predicted. A neuroprotec-
tive function of stefin B was proposed in epilepsy on the basis
of increased expression in forebrain neurons following seizure
activity in rats (D’Amato et al., 2000). Of note, stefin B binds to
histones and indirectly regulates the cell cycle through inhibition
of cathepsin L in the nucleus (Ceru et al., 2010a). The possibility
that stefin B dimers or oligomers would signal cellular pathology
to the nucleus should also be considered and proper experi-
ments conducted. If such alternative functions were lost in EPM1
mutants, the consequences could also lead to neurodegeneration.
The gain in toxic function resulting from protein aggrega-
tion was predicted for some missense and stop mutants (Ceru
et al., 2005). The cytotoxicity of the stefin B aggregates has been
proved and also that the aggregates form intracellularly – as will
be described in more detail in the following section. In the case of
the EPM1mutants affecting protein sequence (not the dodecamer
repeats in the promoter region), which are prone to aggregate in
cells, it is not clear whether the protein’s mis-folding and aggre-
gation are responsible for augmenting progression of the disease
and neurodegenerative changes or whether it is the lack of the
protein’s protective function (both as protease inhibitor or some
alternative function as noted above) or, a combination of the two.
POSSIBLE INVOLVEMENT OF STEFIN B IN INNATE IMMUNITY
Glial cells have several important and protective roles in the brain,
providing support and nutrition to neurons, maintaining home-
ostasis of metabolites and metal ions. They also form myelin,
and participate in signal transmission in the central nervous sys-
tem (CNS). There are two groups of glial cells in the CNS: the
macroglia, including astrocytes, oligodendrocytes, and ependy-
mal cells, and themicroglia.Microglia are effector cells in the CNS
that participate in the innate immune defence by continuously
surveying their cellular environment in the brain parenchyma
(Hanisch and Kettenmann, 2007).
In chronic neurodegenerative diseases the innate immune
response is dominated by microglia (Dheen et al., 2007). It
has been shown that excessive reactive gliosis by release of the
S100β protein inhibits neurogenesis and leads to neuroinflamma-
tion and neurodegeneration (Van Eldik and Wainwright, 2003).
However, not only the microglia activation but also systemic CNS
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inflammation contributes to disease progression, as observed in
animal models of acute neurodegeneration (Palin et al., 2008),
ischemia (McColl et al., 2008) and AD (Dunn et al., 2005).
Namely, CNS inflammation can lead to a dysfunctional uptake of
glutamate in astrocytes which causes excitotoxicity (Lobsiger and
Cleveland, 2007).
In different inflammatory or ischemic conditions, reactive fib-
rillary astrocytes produce dense microglial scars that build a
physical barrier between damaged and healthy cells. This biolog-
ical phenomenon appears to be a prevalent adaptation against
neurodegeneration. Glial activation has also been suggested in
various neurodegenerative diseases such as AD and prion dis-
ease (Eikelenboom et al., 2002; Mandrekar-Colucci and Landreth,
2010), PD (Tansey et al., 2007) and epilepsy (Ivens et al., 2007).
Microglial activation could in fact be one of the main causes
of neuronal death (Herrup, 2010) even though studies on post-
mortem human AD brain suggest a lack of effective phagocytosis
in the clinical samples. However, in stefin B KO mice it has
recently been shown that there is localized glial activation in brain
regions with significant neural loss that precedes the appearance
of myoclonus, which confirms the pathology of excessive glial
activation (Tegelberg et al., 2012). Furthermore, neuronal atro-
phy in the cerebellum (particularly the Purkinje cells), the cortex
and the hippocampus are observed in stefin B deficient mice and
EPM1 patients (Eldridge et al., 1983; Pennacchio et al., 1998;
Koskenkorva et al., 2009). Abundant gliosis (e.g., production of
dense glial scars) appears in these regions (Shannon et al., 2002).
Genes involved in increased apoptosis and glial activation become
overexpressed (Lieuallen et al., 2001).
In accordance with a neuroprotective role for both cystatins
C and stefin B (which can to some extent replace each other), Kaur
et al., 2010 have shown that cystatin C overexpression in stefin B
deficient mice decreases the level of gliosis (Kaur et al., 2010). As
for the innate immunity, cystatin C was shown to increase the lev-
els of inducible NO synthase (iNOS) and enhance IFN-γ-induced
activation of cystatin C KO macrophages (Frendeus et al., 2009).
Cystatin C was also reported to induce microglial activation and
neurotoxicity using a rat neuron-microglial model for PD (Dutta
et al., 2012). By now it only has been reported that stefin B is
involved in the invertebrate innate immunity response (Lefebvre
et al., 2004). On the other hand, cystatin C induced autophagy in
a neuronal cell-based model, which also exerts neuroprotective
effects (Tizon et al., 2010b).
Furthermore, glial cells of the hippocampus and cerebellum
participate in synaptic transmission and regulate the clearance of
neurotransmitters from the synaptic cleft. These cells surround
the synaptic junctions and control neuronal excitability and the
strength of synaptic transmission through release of calcium,
other ion-fluxes cell adhesion molecules, and specialized signal-
ing molecules released from synaptic and nonsynaptic regions
of the neuron (Fields and Stevens-Graham, 2002). Wang et al.
(2012) have recently shown that astrocytes modulate the activity
of Ca2+-dependent uptake of the extracellular K+. Active con-
trol of the extracellular K+ concentration thus provides astrocytes
with a simple yet powerful mechanism for rapid modulation of
network activity. It is possible that astrocyte calcium signaling and
epilepsy are connected (Carmignoto and Haydon, 2012). In fact,
the astrocytic activation that occurs in epilepsy results in reduced
buffering of extracellular potassium and glutamate, which is sug-
gested to underlie frequency-dependent neuronal hyperexcitabil-
ity (David et al., 2009). Gliosis and reactive astrocytes were also
recently shown in neuronal ceroid lipofuscinosis, a type of PME
(Macauley et al., 2011). Therefore, the role of stefin B in astrocytes
certainly deserves more study.
PROTEIN AGGREGATION AS A TRIGGER FOR
NEURODEGENERATIVE DISEASES
Neurodegenerative diseases are becoming an increasing problem
in the Western world due to the prolonged life span of aging
populations. Although presenting with different symptoms, they
share a common protein mis-folding that leads to aggregation.
Here we present a brief overview of the status of our knowledge
of protein aggregation in connection with neurodegenerative dis-
ease. We then describe, in more detail, aggregation observed in
mammalian cell lines of human stefin B, the protein affected in
EPM1.
AD is marked by senile plaques, which are extracellular inclu-
sions of predominantly amyloid-β (Aβ) peptide derived fromAPP
(amyloid precursor protein). APP is a transmembrane protein
of approximately 700 amino acid residues, which has impor-
tant prosurvival functions in the cell. It is normally processed
by membrane proteolysis (by enzymes called secretases) into
an Aβ (1–40) peptide. The more hydrophobic Aβ (1–42) pep-
tide is produced in a higher proportion in some familial cases
and also forms oligomeric species and extracellular amyloid
plaques. In addition, tau protein becomes hyperphosphorylated
and forms intracellular neurofibrillary tangles (Querfurth and
Laferla, 2010).
PD is caused by selective and progressive degeneration of pig-
mented dopaminergic (DA) neurons in the substancia nigra pars
compacta (SNpc). One important feature of PD is the presence
of eosinophilic, cytoplasmic inclusions of fibrillar aggregates of
misfolded protein, termed Lewy bodies, which appear in affected
brain areas. The exact composition of Lewy bodies is unknown,
except for (ubiquinated) α-synuclein and proteins associated with
the genetic forms of PD such as parkin and synphilin (Bossy-
Wetzel et al., 2004). These and other proteins linked to PD
(e.g., redox-regulated chaperone DJ-1, leucine-rich repeat kinase
2 LRRK2, serine/threonine kinase PINK1) provide further insight
into the pathogenesis of PD. Currently, the main mechanism
underlying selective dopaminergic neuron death appears to be a
severe mitochondrial dysfunction (Bueler, 2009).
Mutation encoding an abnormal expansion of polyglutamine
repeats in a protein called huntingtin is the underlying cause
of HD. Disease severity depends on the length of the polyQ
stretch. Repeats longer than 37 are clearly linked to HD. The
expanded polyQ stretch of the mutated huntingtin induces con-
formational change to a cross-β structure, resulting in aggregates
that are found in dendrites and nuclei of the affected neurons.
The aggregates, especially soluble oligomeric forms, are thought
to confer a gain in toxic function via transcriptional deregula-
tion, binding and sequestering of selective transcription factors,
protein aggregation, causing excitotoxicity (Friedlander, 2003;
Bossy-Wetzel et al., 2008). Symptoms of HD include movement
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disorder (Huntington’s chorea), cognitive dysfunction,  and psy-
chiatric symptoms such as depression and psychosis. This results
from selective loss of the long projection GABAergic neurons,
known as medium spiny neurons, which are responsible for
control of movement both of the body and limbs (Bossy-Wetzel
et al., 2008).
Prion diseases (e.g., kuru, fatal familial insomnia) can orig-
inate spontaneously or are inherited. The main component
of prion pathology is a misfolded, partially protease-resistant
“scrapie” conformer (PrPSc) derived from a normal cell surface
protein, the cellular prion protein (PrPC), which exerts an anti-
oxidative function. Other pathological features common to prion
diseases and other neurodegenerative disorders are astrocytosis
and vacuolization (Sakudo and Ikuta, 2009).
Cellular prion protein (PrPC) was found to function as a high
affinity surface receptor for soluble Aβ-oligomers in neurons and
is therefore a mediator of the Aβ-oligomer induced synaptic dys-
function. This links ADwith infective human prion diseases, such
as variant Creutzfeldt-Jakob disease (CJD) (Lauren et al., 2009).
The infectivity of other amyloid forms connected to PD and HD
has also been studied, however, there is no direct evidence of
infectious forms of Aβ, tau, huntingtin or α-synuclein (Cushman
et al., 2010).
There are more than 25 such amyloid forming proteins. To
learn of such proteins and the corresponding diseases see Tables
in reviews (Yon, 2002; Polajnar et al., 2012).
DEFENCE OF CELLS AGAINST TOXIC EFFECTS OF PROTEIN
AGGREGATES
Evidence exists that soluble, prefibrillar aggregates are more cyto-
toxic than mature and insoluble amyloid fibrils (Bucciantini
et al., 2002, 2004, 2005; Stefani, 2010). Smaller protein aggre-
gates are transported in a microtubule-dependant manner to the
centrosome in the vicinity of the nucleus, and are sequestered
into vesicular structures, called aggresomes (Kopito, 2000). The
aggresome serves as a storage compartment for intracytoplas-
mic protein aggregates. One suggestion is that the formation
of aggresomes is a protective mechanism that sequesters the
toxic species of abnormally folded polypeptides (Corboy et al.,
2005).
There are several mechanisms in cells that help prevent toxicity
of protein aggregates. These comprise various chaperone pro-
teins, the ubiquitin proteasome system (UPS) and autophagy. The
latter often serves as the last line of defence.
While UPS malfunctioning has already been linked to neu-
rodegenerative disorders, important links between autophagy
and neurodegeneration have also become evident (Ventruti and
Cuervo, 2007). Studies have revealed cross-talk between UPS and
autophagy, suggesting a coordinated and complementary interac-
tion between these two degradation systems, especially in cases
of cellular stress (Nedelsky et al., 2008). Autophagy is a degrada-
tive and recycling process of many cellular components ranging
from long-lived proteins to whole organelles. It increases during
starvation, oxidative stress and hypoxia, i.e., pathological con-
ditions that cause cellular stress. Macroautophagy is the most
common type of autophagy. The turnover of cell debris occurs
via double-membrane vesicles termed autophagosomes in which
it is degraded by lysosomal proteases in the low pH environment.
Cytosolic proteins, as well as misfolded secretory proteins and
some membrane proteins exported from the endoplasmic reticu-
lum to the cytosol by retrograde transport, are normally degraded
by UPS, however, autophagy is the predominant way of aggre-
somes clearance (Chin et al., 2010).
Autophagy can be impaired in many neurodegenerative dis-
orders [for review (Wong and Cuervo, 2010)]. We recently
proposed that autophagy may also be impaired in progressive
myoclonus epilepsies, including EPM1 and EPM2 (Polajnar and
Zerovnik, 2011). Impairment of autophagy could be due to dys-
function in the lysosomal pathway and/or the susceptibility of
the lysosome to oxidative stress that can result from excessive
protein aggregation, mitochondrial dysfunction or other cellular
defects. Furthermore, amyloid forming proteins in their prefib-
rillar and oligomeric forms can disrupt membrane integrity and
even make channels (pores) which resemble those of bacterial
pore-forming toxins [for review see (Butterfield and Lashuel,
2010)]. One of the biggest sources of reactive oxygen species
(ROS) are (intact) mitochondria. Production of ROS can be sig-
nificantly increased in various neurodegenerative disorders due
to mitochondrial defects in the respiratory and energy chains
(Lim et al., 2008; Vila and Perier, 2008; Rhein et al., 2009).
Indeed, it has been observed that the high level of H2O2 that
originates from mitochondria of starved cells acts as a sig-
nal to initiate autophagy (Scherz-Shouval and Elazar, 2007).
Dysfunctional mitochondria can finally collapse and proapop-
totic molecules are released which leads to cell death (Halestrap,
2009).
Recently, cystatin C was shown to induce autophagy via mTOR
inhibition, which is pro-survival for the cell under stress con-
ditions (Tizon et al., 2010a). Cystatin C has diverse functions,
the best known being inhibition of cysteine proteases such as
cathepsins, papain (Brzin et al., 1984; Turk and Bode, 1991)
and legumain (Alvarez-Fernandez et al., 1999). Furthermore, cys-
tatin C was shown to interact with Aβ and to inhibit formation
in vitro of Aβ fibrils (Sastre et al., 2004) and oligomers (Selenica
et al., 2007; Tizon et al., 2010a). Cystatin C bound to the solu-
ble Aβ in the brains of Aβ amyloid depositing transgenic mice
and inhibited the aggregates and deposites of Aβ plaques in the
brain (Kaeser et al., 2007; Mi et al., 2007). Cystatin C could exert
a neuroprotective function by either preventing cell death, or
promoting cell survival and neurogenesis.
Stefin B is part of the same cystatin superfamily as cystatin
C and inhibits cathepsins B, C, H, K, L and S (Turk et al.,
1986; Lenarcic et al., 1996; Dahl et al., 2001). Similar to cys-
tatin C, stefin B inhibits Aβ fibril growth, however, this binding
is dependent on its oligomeric state (Skerget et al., 2010), with
the tetramer showing the highest affinity for Aβ. Oligomers of
stefin B have been observed in cells (Cipollini et al., 2008). It
also has been shown that the endogenous protein forms smaller,
occasional aggregates, which become more abundant upon pro-
teasome inhibition or in the presence of mutations (e.g., R68X)
(Ceru et al., 2010b). Recently, neuronal cytoplasmic and intranu-
clear inclusions containing the lysosomal proteins cathepsin B
and CD68 and FUS, respectively, were identified in one EPM1
patient (Cohen et al., 2011).
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HUMAN STEFIN B EPM1 MUTANTS AGGREGATE READILY in vitro
Stefin B has served as a good model system with which to study
amyloid fibril formation and prefibrillar aggregation (Zerovnik,
2002; Anderluh et al., 2005; Rabzelj et al., 2005; Zerovnik et al.,
2007). Its sequence, which is prone to oligomerise and form
amyloid fibrils, is 52% identical to that of a more stable homo-
logue, stefin A, which is predominantly a monomeric protein and
can only be pushed to fibrils under extreme conditions (Jenko
et al., 2004). The stability and aggregation propensity of sev-
eral stefin B mutants and one iso-form (variant bearing Y31)
have been studied (Jenko et al., 2004; Kenig et al., 2004; Rabzelj
et al., 2005; Kenig et al., 2006; Ceru et al., 2010b). In 2005
we proposed (Ceru et al., 2005) that some of the mutants of
human stefin B found in EPM1 patients, which are not active
as cysteine protease inhibitors, may be more prone to aggre-
gation than the wild-type protein and that they also proba-
bly aggregate inside the mammalian cell, producing additional
gain in toxic function (Zerovnik et al., 2002; Anderluh et al.,
2005).
Sizes and morphology of the prefibrillar aggregates have been
determined and are similar to those of other amyloid form-
ing proteins (Ceru et al., 2008). Furthermore, toxicity studies
showed that the prefibrillar oligomers of stefin B are toxic to
cells (Ceru et al., 2008; Ceru and Zerovnik, 2008). A consen-
sus has been reached that the mechanism of amyloid cytotoxicity
involves membrane perturbation or perforation (Stefani, 2010).
As observed for a number of amyloid forming proteins, stefin
B binds to acidic phospholipid bilayers (Anderluh et al., 2005;
Rabzelj et al., 2008).
Several mutants of stefin B, occurring in EPM1 patients, which
bear changes in the coding region of the protein sequence were
prepared in Esherichia coli. Their inhibitory activity as cysteine
protease inhibitors has also been measured. The G4R mutant
showed no inhibitory activity at all, while G50E and Q71P
mutants showed much lower inhibitory activity than the wild
type protein. The fragment R68X, which stays unfolded, was not
active, either.
It has been shown in vitro that the fragment R68X forms
amyloid-fibrils very rapidly, even at neutral pH and under mild
conditions, whereas the G4R mutant exhibits a prolonged lag
phase, during which prefibrillar aggregates accumulate (Rabzelj
et al., 2005). These aggregates and oligomers, when added to the
cell medium, produced a toxic effect (Ceru et al., 2008). The
isolated higher-order oligomers bound effectively to lipid mono-
layers and were shown to get internalized to the cell cytoplasm
from the medium where they reduced cell viability (Ceru et al.,
2008; Ceru and Zerovnik, 2008; Rabzelj et al., 2008).
G50E and Q71P mutants, on the basis of CD and ANS fluores-
cence spectra, possess secondary and tertiary structures similar to
that of the wild type, only they are slightly more unfolded and
have exposed hydrophobic surfaces (Polajnar et al., 2011). The
R68X fragment is unfolded and transforms to amyloid-like fibrils
at neutral pH (Rabzelj et al., 2005). Interestingly, and in distinc-
tion from other missense EPM1mutants, G4R is a properly folded
and compact protein of similar stability to the wild type protein
but exhibits a four times longer lag phase during fibril formation
(Rabzelj et al., 2005).
HUMAN STEFIN B EPM1 MUTANTS FORM AGGREGATES IN
CELLS AND SHOW CYTO-TOXICITY
Cell culture experiments have confirmed that stefin B is prone to
form oligomers and aggregates in cells (Cipollini et al., 2008).
The endogenous protein forms small oligomers while the wild
type stefin B and its EPM1 mutants aggregate upon overexpres-
sion, the wild type to a much lesser extent (Ceru et al., 2010b).
This suggests that the regulation of both expression and oligomer-
ization of stefin B is crucial to the cell and may have a role in
neurodegeneration.
As compared to the wild-type protein, all the missense mutants
we have studied formed larger cytosolic, and often also per-
inuclear, aggregates (see, Figure 1). The aggregates of stefin B
mutants have many of the molecular characteristics of aggre-
somes (Kopito, 2000) as partially demonstrated previously (Ceru
et al., 2010b). In contrast to the belief that aggresomes could be
cytoprotective (Nedelsky et al., 2008), in our case the cells pre-
senting more abundant aggregates were less viable. The partial
co-localization of stefin BR68X aggregates with LC3 indicates that
the aggresomes could be targeted for autophagic clearance (Ceru
et al., 2010b).
The G50E and Q71P stefin B mutants also form large perinu-
clear aggregates that cause collapse of the cell and fragmentation
of the nucleus [Figure not shown, data were presented at FEBS
2011 conference (Polajnar et al., 2011)].
It has been demonstrated (Ceru et al., 2008) that the R68X
fragment forms aggresome-like structures at the nucleus which
are cytotoxic, whereas the G4R mutant and the wild type pro-
tein form smaller aggregates under conditions of over-expression
or proteasome inhibition. Consistent with this, patients bearing
one allele of R68X and the other of the usual dodecamer repeat
in the cystatin B gene, show more severe pathology and clini-
cal symptoms (Koskenkorva et al., 2011). These findings raise
the question as to whether the oligomers/aggregates are cytotoxic
or whether the inclusions are instead protective, as suggested by
some (Kopito, 2000).
Why no-one has reported that EPM1 would be a conforma-
tional disorder, bearing protein aggregates of stefin B intracel-
lularly? Only rare studies of samples from human patients with
EPM1 can be found in the literature. Also, mutations occurring
in the exonic or intronic region of cystatin B gene account for
only 10% of the EPM1 patients. Protein aggregates have been
discovered recently in the brain of one EPM1 patient, however,
these aggregates did not contain stefin B (Cohen et al., 2011).
This was a patient with a dodecamer expansion in the promoter
region which causes decreased expression of stefin B protein.
We are not aware of detailed neuropathogical studies performed
on patients with additional mutations (especially those in the
transcript region). Of note, it was reported that patients with
an R68X mutation, which leads to expression of a truncated
version of stefin B protein, have more severe myoclonus, drug-
resistant tonic-clonic seizures and lower cognitive performance.
Some were even reported to be psychotic (Koskenkorva et al.,
2011). Our results, albeit obtained from experiments on cell cul-
tures, strongly suggest that stefin B becomes more toxic when it
forms aggregates and thus should be considered in future human
pathological studies.
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FIGURE 1 | Perinuclear aggregates of the EPM1 R68X mutant and of the
most aggregate prone wild-type variant stefin B with Y31 (both fused
with green fluorescent protein T-Sapphire). The nuclei were labeled with
propyl-iodide – PI (red color). The wild type protein does not form substantial
aggregates at the same level of expression. For Figure 1, from the journal
“Amyloid”, we obtained the copyright by Informa Healthcare via RightsLink.
CONCLUSIONS
In vitro experiments have confirmed that most of the exonic
EPM1 mutants of human stefin B are misfolded proteins, either
completely unfolded such as R68X, or partially unfolded such
as G50E and Q71P, exposing increased amounts of hydropho-
bic patches. These structural characteristics indicate instability
and lead to protein aggregation. An exception is the G4R mutant
which possesses completely folded secondary and tertiary struc-
tures but still loses its protease inhibitor function. When over-
expressed, even this mutant can form diffuse aggregates while the
other EPM1 mutants, G50E, Q71P and R68X, form large perinu-
clear aggregates that sometimes extend over the whole cytoplasm.
The aggregates are toxic (Ceru et al., 2010b) which could arise
through a different mechanism, e.g., pore formation in cellular or
plasma membranes, increased oxidative stress or autophagy dis-
ruption. Data confirming such a mechanism of toxicity are being
collected.
We argue that, regardless of the fact that in EPM1 patients no
intracellular inclusions of stefin B have been observed thus far
(but a conference report by Cantor that mast and lung cells have
vesicular inclusions of unknown composition—Eva Žerovnik
personal communication), the aggregation of the EPM1 mutants
R68X, G50E, Q71P and, to a smaller extent G4R, could modulate
the phenotype of the disease, by a gain in toxic function.
There can be several reasons why no inclusion bodies have
been observed in patients. Either, the rare cases of these mutants
(only one allele of about 10% of EPM1 cases may bear a gene
mutation to code changes in the sequence such as R68X, G50E
and P71Q) might have been overlooked, or lack of stefin B rather
contributes to aggregate formation of other proteins—if it acted
as a chaperone (Taler-Vercic and Zerovnik, 2010).
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